Accendra Health's Reset: CEO Retirement, Payor Audit Headwinds, and a Sharper Focus on Free Cash Flow
A New CEO and a Strategic Pause
When Accendra Health's President and CEO Edward Pesicka announced his intention to retire by the end of 2026 on the second-quarter call, it capped an eight-year tenure that saw the company stabilize, navigate COVID, divest its P&HS segment, and complete a balance-sheet optimization. “The decision to retire is never easy. However, after considerations with my family and careful thought, I've decided that now is the right time.” — Edward Pesicka, Chief Executive Officer · 2026-08-10 The retirement is a clear signal that the company is entering a new chapter, but the quarter's operational and financial missteps suggest the next leader will inherit a business still in flux.
The second quarter did not meet internal expectations: revenue grew only 2% ex the large commercial payor exit, and adjusted EBITDA of just over $60 million was flat sequentially. Management pointed to three culprits: slower-than-expected growth, delayed cost reductions, and a worsening collections profile. The push to Center of Excellence for sleep is still early, and the company's Jane Doe – a placeholder for the audit paperwork – has become a fixture of the earnings call vocabulary.
The Payor Audit Drag
The most pressing issue is the spike in payor audits. CFO Jonathan Leon explained that the volume of audited items grew exponentially, tying up resources and delaying cash receipts. “What was unusual is a couple of months ago, we started seeing the actual – not number of audits, the number of items audited actually begin to increase at an exponential rate.” — Jonathan Leon, Chief Financial Officer · 2026-08-10 This directly hit the collection rate – the company's internal metric for how much of gross revenue is ultimately collected – with a ~$20 million adverse impact in the first half, and it is the primary reason the company's free cash flow guidance was slashed to breakeven or slightly positive for the full year.
Leon is confident the issue is temporary, noting that "we are making significant progress in the last couple of weeks with these payors," but the market is not yet convinced – the stock is down roughly 57% in the last 90 days.
In a stark acknowledgement of the payor audit environment, management announced a new NOL rights plan and an at-the-market equity program to protect the company's substantial net operating loss carryforwards.
We saw that we were halfway to potentially having a problem should the shareholders continue to buy… It was brought to our attention, and we look back at trading history and saw that it was probably a prudent thing to do to protect shareholder interest and the value of those NOLs.
Balance Sheet and Free Cash Flow
The balance-sheet optimization completed in June reduced total debt by almost $400 million, but the business remains highly leveraged. Free cash flow (less SBC) was -$45 million in the latest quarter, a -7.1% margin, and the trend has deteriorated sharply over the past year. The company expects to return to ~$100 million of annual free cash flow in a "normalized" year, but management's own comments suggest 2026 is unlikely to be that year.
"We'll be drawing the revolver occasionally as based on lumpiness in working capital needs," said Leon, but the larger story is the ATM program and the NOL rights plan – measures that, even if small, signal that the company is actively managing every lever to protect cash and shareholder value.
Outlook: A Step Back, Then a Step Forward
Guidance for 2026 was revised down to revenue of $2.45–2.55 billion and adjusted EBITDA of $300–320 million. The fourth quarter is expected to be the strongest, but the bridge to 2027 remains reliant on cost cuts that are only now resuming, new commercial agreements, and the eventual normalization of payor audits.
The company has taken out more than $125 million of annualized costs, and a second wave of reductions is underway. payor audit issues, however, are a reminder that the company's revenue cycle is not yet stable. As Ed Pesicka said in his prepared remarks, "we have already implemented a number of these initiatives and have additional actions planned that are designed to streamline our operations, improve efficiencies and reduce costs." The next CEO will have the playbook – but will also face a market that has priced in a long recovery.